Created by the Grimaud group, the Nantes company Vivalis became Valneva in 2013. It is continuing its international development in antibody and vaccine research.
"The traditional industrial businesses in the region are willing to invest in new technologies, and Valneva is proof," says Frank Grimaud, President of Valneva.
Biotechnology: innovation is key to Valneva's business
Following the merger of the Nantes firm Vivalis and the Austrian firm Intercell, Valneva's main objective is antibody discovery using innovative methods.
Their first vaccine licensed in more than 35 countries
Valneva also designs, develops and markets vaccines, through its Nantes-based R&D site Vaccines, antibodies and cell lines, which benefits from the rich network of health and biotherapy research in Nantes.
In 2007, the company received the green light from WHO for the distribution of its new vaccine for Japanese encephalitis in vulnerable regions in Asia (Japan, India and Taiwan).
A tuberculosis vaccine coming soon?
Valneva's partners - Statens Serum Institut (SSI) and Aeras - are using Valneva's vaccine adjuvant - IC31 - to develop a tuberculosis vaccine.
Clinical studies are currently underway.
For Valneva, partnerships are essential for success in the field of biotechnology.
The company works with Novartis, Biological E., Kaketsuken, Geovax and many others.